{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":35,"description":"Patients undergoing ASCT for MM who were ≥60 years old or had AL amyloidosis were randomized to receive either a standard (4-6×106 cells/kg) of CD34+ cells after melphalan 200 mg/m2.","id":"EG000","otherNumAffected":1,"otherNumAtRisk":35,"seriousNumAffected":1,"seriousNumAtRisk":35,"title":"Standard Dose Stem Cell Group"},{"deathsNumAffected":0,"deathsNumAtRisk":40,"description":"Patients undergoing ASCT for MM who were ≥60 years old or had AL amyloidosis were randomized to receive high dose (10-15×106 cells/kg) of CD34+ cells after melphalan 200 mg/m2.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":40,"seriousNumAffected":0,"seriousNumAtRisk":40,"title":"High Dose Stem Cell Group"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":35,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":40,"numEvents":0}],"term":"Graft Failure"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":35,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":40,"numEvents":0}],"term":"Graft Failure"}],"timeFrame":"Adverse event collection through the last day of active treatment day 0 (stem cell infusion) up to 30 days as outlined in the treatment plan."}